UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Mayo Clinic proceedings, ISSN 0025-6196, 2015, Volume 90, Issue 8, pp. 996 - 1000
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Drug Costs | United States - epidemiology | Neoplasms - economics | Humans | Patient Participation | Patient Advocacy | Antineoplastic Agents - economics | Neoplasms - epidemiology | Prescription Fees | Neoplasms - drug therapy | Antimitotic agents | Cancer patients | Patient outcomes | Economic aspects | Dosage and administration | Drug therapy | Antineoplastic agents | Index Medicus | Abridged Index Medicus
Journal Article
2.
Full Text
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 12, pp. e538 - e548
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Multiple Myeloma - pathology | Prognosis | Renal Insufficiency - diagnosis | Multiple Myeloma - diagnosis | Renal Insufficiency - pathology | Humans | Bone Marrow Cells - pathology | Renal Insufficiency - complications | Biomarkers, Tumor | Multiple myeloma | Diagnosis | Index Medicus | Medicin och hälsovetenskap
Journal Article
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1195 - 1206
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Prognosis | Multiple Myeloma - mortality | Humans | Middle Aged | Pyrazines - administration & dosage | Neoplasm Recurrence, Local - drug therapy | Male | Neoplasm Recurrence, Local - mortality | Indoles - administration & dosage | Dose-Response Relationship, Drug | Neoplasm Recurrence, Local - pathology | Multiple Myeloma - drug therapy | Hydroxamic Acids - administration & dosage | Adult | Female | Boronic Acids - administration & dosage | Bortezomib | Dexamethasone - administration & dosage | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Kaplan-Meier Estimate | Treatment Outcome | Remission Induction | Disease-Free Survival | Maximum Tolerated Dose | Multiple Myeloma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Infusions, Intravenous | Medical colleges | Care and treatment | Relapse | Dexamethasone | Multiple myeloma | Clinical trials | Product development | Diseases | Index Medicus | Medicin och hälsovetenskap
Journal Article
The lancet oncology, ISSN 1470-2045, 2013, Volume 14, Issue 11, pp. 1129 - 1140
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Prognosis | Follow-Up Studies | Multiple Myeloma - mortality | Humans | Middle Aged | Pyrazines - administration & dosage | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Male | Neoplasm Recurrence, Local - mortality | Neoplasm Recurrence, Local - pathology | Multiple Myeloma - drug therapy | Aged, 80 and over | Hydroxamic Acids - administration & dosage | Adult | Female | Boronic Acids - administration & dosage | Bortezomib | Double-Blind Method | Survival Rate | Multiple Myeloma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Neoplasm Staging | Drug Resistance, Neoplasm - drug effects | Medicine, Experimental | Medical research | Medical colleges | Care and treatment | Multiple myeloma | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2016, Volume 17, Issue 8, pp. e328 - e346
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Multiple Myeloma - drug therapy | Practice Guidelines as Topic - standards | Humans | Neoplasm, Residual - diagnosis | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm, Residual - chemically induced | Consensus | Multiple myeloma | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 3, pp. 333 - 342
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Thalidomide - adverse effects | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Melphalan - adverse effects | Neoplasms, Second Primary - chemically induced | Humans | Angiogenesis Inhibitors - adverse effects | Care and treatment | Analysis | Cancer | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2016, Volume 387, Issue 10027, pp. 1551 - 1560
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Drug Administration Schedule | United States | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Kaplan-Meier Estimate | Neoplasm Recurrence, Local - drug therapy | Antibodies, Monoclonal - therapeutic use | Drug Resistance, Neoplasm | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Spain | Canada | Disease-Free Survival | Multiple Myeloma - drug therapy | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adult | Female | Aged | Drugs | Medical colleges | Biological products | Multiple myeloma | Monoclonal antibodies | Product development | Lymphomas | Drug therapy | Care and treatment | Analysis | Studies | Protease inhibitors | Hematology | Stem cells | Cytotoxicity | Patients | Drug dosages | Slopes | Therapy | Schedules | Intravenous administration | Stem cell transplantation | Transplantation | Drug screening | Evidence-based medicine | Immunosuppressive agents | Randomization | CD38 antigen | Autografts | Anemia | Immunomodulation | Research & development--R&D | FDA approval | Survival | Proteasome inhibitors | Asthma | Inhibitors | Interactive systems | Response rates | Index Medicus | Abridged Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 13, pp. 1503 - 1512
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Glycine - analogs & derivatives | Glycine - therapeutic use | Prognosis | Follow-Up Studies | Multiple Myeloma - mortality | Humans | Middle Aged | Male | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Aged, 80 and over | Adult | Female | Safety | Dexamethasone - administration & dosage | Lenalidomide | Administration, Oral | Proteasome Inhibitors - administration & dosage | Survival Rate | Thalidomide - administration & dosage | Maximum Tolerated Dose | Multiple Myeloma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Neoplasm Staging | Boron Compounds - therapeutic use | Medicine, Experimental | Medical research | Care and treatment | Safety and security measures | Dexamethasone | Multiple myeloma | Analysis | Index Medicus
Journal Article